• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2020 年至 2022 年 SARS-CoV-2 主蛋白酶抑制剂的研究进展。

The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.

机构信息

Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.

Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China.

出版信息

Eur J Med Chem. 2023 Sep 5;257:115491. doi: 10.1016/j.ejmech.2023.115491. Epub 2023 May 22.

DOI:10.1016/j.ejmech.2023.115491
PMID:37244162
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10201905/
Abstract

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (M) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19. Many SARS-CoV-2 M inhibitors have been reported, including covalent and noncovalent inhibitors. The SARS-CoV-2 M inhibitor PF-07321332 (Nirmatrelvir) designed by Pfizer has been put on the market. This paper briefly introduces the structural characteristics of SARS-CoV-2 M and summarizes the research progress of SARS-CoV-2 M inhibitors from the aspects of drug repurposing and drug design. These information will provide a basis for the drug development of treating the infection of SARS-CoV-2 and even other coronaviruses in the future.

摘要

新型冠状病毒病 2019（COVID-19）由严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起，已在全球范围内传播。SARS-CoV-2 的主要蛋白酶（M）在病毒复制和转录中起着核心作用，是抗击 COVID-19 的一个有吸引力的药物靶点。已经报道了许多 SARS-CoV-2 M 抑制剂，包括共价和非共价抑制剂。辉瑞公司设计的 SARS-CoV-2 M 抑制剂 PF-07321332（Nirmatrelvir）已上市。本文简要介绍了 SARS-CoV-2 M 的结构特征，并从药物再利用和药物设计两个方面总结了 SARS-CoV-2 M 抑制剂的研究进展。这些信息将为未来治疗 SARS-CoV-2 甚至其他冠状病毒感染的药物开发提供依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/ed7b1716cf1d/gr12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/59e0716435f8/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/4a7433f1d804/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/08a32b44186e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/518f86cd71ef/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/a0c6096c8c46/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/4d3cc53a60ef/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/6de638ad58b4/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/fdf11ccbc9fb/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/40e2c8c1a4e1/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/7f434836a6ac/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/44092ad071a1/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/3eff5ccac424/gr11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/ed7b1716cf1d/gr12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/59e0716435f8/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/4a7433f1d804/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/08a32b44186e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/518f86cd71ef/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/a0c6096c8c46/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/4d3cc53a60ef/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/6de638ad58b4/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/fdf11ccbc9fb/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/40e2c8c1a4e1/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/7f434836a6ac/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/44092ad071a1/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/3eff5ccac424/gr11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f713/10201905/ed7b1716cf1d/gr12_lrg.jpg

相似文献

1
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.2020 年至 2022 年 SARS-CoV-2 主蛋白酶抑制剂的研究进展。
Eur J Med Chem. 2023 Sep 5;257:115491. doi: 10.1016/j.ejmech.2023.115491. Epub 2023 May 22.
2
Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.SARS-CoV-2 M 抗病毒药物的优化规则：冠状病毒蛋白酶活性位点的整体对接和探索。
Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942.
3
Conventional Understanding of SARS-CoV-2 M and Common Strategies for Developing Its Inhibitors.对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）M蛋白的传统认识及其抑制剂开发的常见策略。
Chembiochem. 2023 Nov 16;24(22):e202300301. doi: 10.1002/cbic.202300301. Epub 2023 Oct 18.
4
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.基于药物再利用的分子对接和动力学模拟预测 SARS-CoV-2 主要蛋白酶的潜在抑制剂的计算机预测。
J Infect Public Health. 2020 Sep;13(9):1210-1223. doi: 10.1016/j.jiph.2020.06.016. Epub 2020 Jun 16.
5
Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors.基于结构发现硫代氨基脲类化合物作为新型冠状病毒主要蛋白酶抑制剂
Future Med Chem. 2023 Jun;15(11):959-985. doi: 10.4155/fmc-2023-0034. Epub 2023 Jul 12.
6
In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.计算机模拟揭示 SARS-CoV-2 主要蛋白酶，提示 NADH 内源性防御在控制大流行冠状病毒感染中的作用。
Viruses. 2020 Jul 26;12(8):805. doi: 10.3390/v12080805.
7
Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.SARS-CoV-2 编码的 M 蛋白酶抑制剂的发现。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00872-20.
8
Anti-HIV and anti-HCV small molecule protease inhibitors in-silico repurposing against SARS-CoV-2 M for the treatment of COVID-19.抗 HIV 和抗 HCV 小分子蛋白酶抑制剂的 SARS-CoV-2 M 计算机重定向用于 COVID-19 的治疗。
J Biomol Struct Dyn. 2022;40(23):12848-12862. doi: 10.1080/07391102.2021.1979097. Epub 2021 Sep 27.
9
Structure of M from SARS-CoV-2 and discovery of its inhibitors.SARS-CoV-2 M 结构与抑制剂的发现
Nature. 2020 Jun;582(7811):289-293. doi: 10.1038/s41586-020-2223-y. Epub 2020 Apr 9.
10
Genetic Surveillance of SARS-CoV-2 M Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid.SARS-CoV-2 M 基因监测显示，在引入蛋白酶抑制剂帕克洛维德之前，其序列和结构高度保守。
mBio. 2022 Aug 30;13(4):e0086922. doi: 10.1128/mbio.00869-22. Epub 2022 Jul 13.

引用本文的文献

1
Antiviral Activity of Medicinal Plant Extracts and Against SARS-CoV-2.药用植物提取物对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的抗病毒活性
Pathogens. 2025 Aug 19;14(8):820. doi: 10.3390/pathogens14080820.
2
Identification of SARS-CoV-2 Main Protease Cleavage Sites in Bovine β-Casein.牛β-酪蛋白中新型冠状病毒主要蛋白酶切割位点的鉴定
Int J Mol Sci. 2025 Jun 18;26(12):5829. doi: 10.3390/ijms26125829.
3
Structural basis for varying drug resistance of SARS-CoV-2 M E166 variants.新冠病毒M E166变体不同耐药性的结构基础
mBio. 2025 Jul 9;16(7):e0262424. doi: 10.1128/mbio.02624-24. Epub 2025 Jun 2.
4
Design, Synthesis, Evaluation, and Molecular Dynamics Simulation of SARS-CoV-2 M Inhibitors.新型冠状病毒M蛋白抑制剂的设计、合成、评估及分子动力学模拟
ACS Med Chem Lett. 2025 Mar 17;16(4):668-674. doi: 10.1021/acsmedchemlett.5c00065. eCollection 2025 Apr 10.
5
Biochemical Screening of Phytochemicals and Identification of Scopoletin as a Potential Inhibitor of SARS-CoV-2 M, Revealing Its Biophysical Impact on Structural Stability.植物化学物质的生化筛选以及东莨菪亭作为严重急性呼吸综合征冠状病毒2主蛋白酶潜在抑制剂的鉴定，揭示其对结构稳定性的生物物理影响
Viruses. 2025 Mar 12;17(3):402. doi: 10.3390/v17030402.
6
Discovering broad-spectrum inhibitors for SARS-CoV-2 variants: a cheminformatics and biophysical approach targeting the main protease.发现针对新冠病毒变异株的广谱抑制剂：一种针对主要蛋白酶的化学信息学和生物物理学方法
Front Pharmacol. 2025 Feb 5;16:1459581. doi: 10.3389/fphar.2025.1459581. eCollection 2025.
7
Computational and evaluation of sumac-derived Rutan compounds towards Sars-CoV-2 M inhibition.漆树衍生的鲁坦化合物对严重急性呼吸综合征冠状病毒2（Sars-CoV-2）M蛋白抑制作用的计算与评估
Front Pharmacol. 2025 Feb 4;16:1518463. doi: 10.3389/fphar.2025.1518463. eCollection 2025.
8
Amino acid T25 in the substrate-binding domain of SARS-CoV-2 nsp5 is involved in viral replication in the mouse lung.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）非结构蛋白5（nsp5）底物结合结构域中的氨基酸T25参与小鼠肺部的病毒复制。
PLoS One. 2024 Dec 6;19(12):e0312800. doi: 10.1371/journal.pone.0312800. eCollection 2024.
9
Asymmetric imidazole-4,5-dicarboxamide derivatives as SARS-CoV-2 main protease inhibitors: design, synthesis and biological evaluation.作为严重急性呼吸综合征冠状病毒2主要蛋白酶抑制剂的不对称咪唑-4,5-二甲酰胺衍生物：设计、合成及生物学评价
RSC Med Chem. 2024 Sep 3;15(11):3880-8. doi: 10.1039/d4md00414k.
10
A potential allosteric inhibitor of SARS-CoV-2 main protease (M) identified through metastable state analysis.通过亚稳态分析鉴定出的一种潜在的严重急性呼吸综合征冠状病毒2型主要蛋白酶（M）变构抑制剂。
Front Mol Biosci. 2024 Sep 6;11:1451280. doi: 10.3389/fmolb.2024.1451280. eCollection 2024.